LOOMIS SAYLES & CO L P - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.

Quarter-by-quarter ownership
LOOMIS SAYLES & CO L P ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2021$19,149,000
+6.5%
408,562
+38.5%
0.02%
+9.1%
Q2 2021$17,985,000295,0250.02%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2021
NameSharesValueWeighting ↓
Aisling Capital Management LP 3,835,722$103,449,00044.18%
Kohlberg Kravis Roberts & Co. L.P. 36,900,661$995,211,00012.26%
SC US (TTGP), LTD. 2,544,738$68,632,0004.69%
Cormorant Asset Management, LP 2,780,885$75,000,0004.31%
Perceptive Advisors 6,706,268$180,868,0004.15%
VIKING GLOBAL INVESTORS LP 26,620,991$717,968,0003.22%
Hillhouse Capital Management 2,035,790$54,905,0001.75%
Alpine Group USVI, LLC 20,000$539,0001.70%
HHLR ADVISORS, LTD. 2,352,900$63,458,0001.42%
SCGE MANAGEMENT, L.P. 588,235$15,865,0000.79%
View complete list of BRIDGEBIO PHARMA INC shareholders